ABCL — AbCellera Biologics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1703057 ·
Last close
$11.03
Market Cap
$3.60B
52W High
$15.02
52W Low
$2.74
ADV30
3,645,785
Next earnings
2026-11-09
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 10,639,000 — -49,679,000 -40,758,000 1,499,864,000 163,800,000 437,364,000
Jun 2026 4,050,000 — -58,923,000 -55,427,000 1,307,575,000 120,065,000 411,555,000
Mar 2026 8,315,000 — -53,180,000 -43,165,000 1,307,112,000 77,063,000 369,029,000
Dec 2025 44,853,000 — -25,266,000 -8,945,000 1,356,950,000 128,513,000 390,046,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,430,000
Investing CF
$-122,038,000
Financing CF
$218,337,000
CapEx
$-17,420,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.64
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-168,832,000
Inventory
$7,569,000
Receivables
$67,276,000
ST Investments
$600,624,000
EBIT TTM
$-187,048,000
Pretax Income TTM
$-170,813,000
Interest Exp TTM
$42,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,170,000
EBITDA
$-199,960,000
Free Cash Flow
$-46,431,124
Enterprise Value
$3,428,156,416
Total Cash
$540,104,000
Total Debt
$135,616,992
Shares Out
326,617,896
Trailing EPS
$-0.48
Book Value
$3.22
ROE
-17.3%
ROA
-10.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 75,128,000 -203,213,000 -146,412,000 1,356,950,000 390,046,000 966,904,000 -131,295,000
Dec 2024 28,833,000 -301,146,000 -162,857,000 1,360,553,000 304,469,000 1,056,084,000 -108,556,000
Dec 2023 38,025,000 -223,052,000 -146,398,000 1,488,094,000 335,776,000 1,152,318,000 -43,877,000
Dec 2022 485,424,000 227,065,000 158,519,000 1,540,907,000 307,630,000 1,233,277,000 277,360,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$66,174,000
NetIncome TTM
$-164,656,000
OpCashFlow TTM
—
Assets (Latest)
$1,307,575,000
Forward EPS
$-0.70

Max Pain — expiry 2027-01-15

max pain strike: $7.00 · spot: $11.02 · call oi: 45,073 · put oi: 29,568
Expected Move to 2027-01-15: ±$2.70 (24.50%) — implied range $8.32 – $13.72 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OGN Organon & Co. $3.65B $13.90 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
TNGX Tango Therapeutics, Inc. $3.75B $22.11 —

News headlines (Yahoo Finance, 1h cache)

AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
2026-11-16 22:12 · Yahoo
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
2026-11-12 13:40 · Yahoo
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
2026-11-12 13:14 · Yahoo
AbCellera Biologics Inc (ABCL) (Q3 2026) Earnings Call Highlights: Breakthrough Hot Flash Data ...
2026-11-10 15:04 · Yahoo
AbCellera (ABCL) Q3 2026 Earnings Call Transcript
2026-11-10 07:02 · Yahoo
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
2026-11-10 02:14 · Yahoo
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 21:35 · Yahoo
AbCellera Reports Q3 2026 Business Results
2026-11-09 21:05 · Yahoo
AbCellera (ABCL) Stock May Look Fully Priced On Book Value
2026-11-06 03:21 · Yahoo
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
2026-11-05 21:05 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-13 12:41:20 2026-11-13 Booth Andrew CFO P - Purchase 11.33 8600 97438